Oregon Law Review : Vol. 88 No. 4, p. 1189-1220 : These Statements Have Not Been Approved by the FDA: Improving the Postapproval Regulation of Prescription Drugs

Simple item page
dc.contributor.authorPage, Christopher R.
dc.date.accessioned2010-11-23T23:53:19Z
dc.date.available2010-11-23T23:53:19Z
dc.date.issued2009
dc.description32 p.en_US
dc.description.abstractIn light of the current regulatory climate, this Comment argues for a new approach to the regulation of prescription drugs approved by the FDA for general sale. The author proposes a reorganization of the agency resulting in the creation of a division of the FDA that focuses solely on actively making regulatory decisions regarding postapproval pharmaceutical products. This new division should be granted the power to effectively gather information and enforce regulations against pharmaceutical companies without needing to consult with another agency or FDA division. The use of this power by a new division would significantly ameliorate much of the public distrust discussed previously.en_US
dc.identifier.issn0196-2043
dc.identifier.urihttps://hdl.handle.net/1794/10845
dc.language.isoen_USen_US
dc.publisherUniversity of Oregon Law Schoolen_US
dc.subjectPharmaceutical industry -- United States
dc.subjectUnited States. Food and Drug Administration
dc.subjectFDA
dc.titleOregon Law Review : Vol. 88 No. 4, p. 1189-1220 : These Statements Have Not Been Approved by the FDA: Improving the Postapproval Regulation of Prescription Drugsen_US
dc.title.alternativeThese Statements Have Not Been Approved by the FDA: Improving the Postapproval Regulation of Prescription Drugsen_US
dc.typeArticleen_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Page.pdf
Size:
133.99 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
2.22 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Oregon Law Review : Vol. 88, No. 4 (2009)